在肝细胞癌中管理非岛状细胞瘤低血糖症,使用放射治疗
Anthony J Chillo1, Sylvester Homsy2, Aye M Thida1
1Hematology and Oncology, State University of New York Downstate Health Sciences University, Brooklyn, USA.
Cureus
|January 27, 2025
概括
非岛屿细胞瘤低血糖症 (NICTH) 是一种罕见的副瘤综合征. 息性辐射疗法 (RT) 在患有NICTH的肝细胞癌患者中改善了血糖控制,证明了RT.
科学领域:
- 在瘤学瘤学.
- 内分泌学 在内分泌学.
- 代谢综合征 代谢综合征
背景情况:
- 非岛屿细胞瘤低血糖症 (NICTH) 是一种与上皮瘤相关的罕见副瘤综合征.
- 肝细胞癌 (HCC) 可以出现罕见的并发症,如NICTH,显著影响患者的发病率.
- 有效管理NICTH,特别是在晚期癌症阶段,仍然是一个临床挑战.
研究的目的:
- 在患有晚期HCC的患者中报告NICTH病例.
- 评估息性放射治疗 (RT) 在管理与NICTH相关的低血糖症方面的疗效.
- 讨论RT在全身癌症治疗中作为NICTH治疗选择的作用.
主要方法:
- 一个37岁的男性患有IVB期HCC和转移性疾病,呈现出复发性低血糖症的病例介绍.
- 诊断工作包括胰岛素生长因子1 (IGF-1) 和胰岛素生长因子2 (IGF-2) 水平,显示高的IGF-2:IGF-1比率与NICTH一致.
- 治疗包括全身治疗 (阿特佐利祖马布,贝瓦齐祖马布),息性RT,类固醇和葡萄糖补充剂.
主要成果:
- 患者表现出NICTH的生化证据, IGF-1受抑制,IGF-2升高.
- 针对肺转移的息性RT后,观察到血糖控制的显著改善和低血糖事件的减少.
- 患者在口服类固醇下出院,这表明通过RT成功控制了低血糖症.
结论:
- 与HCC相关的NICTH是一种罕见但严重的并发症,需要多学科管理.
- 息性RT可以成为改善NICTH血糖控制的有效策略,特别是当手术切除是不可行的时.
- 整合RT与全身疗法可能提供一种可行的方法来管理NICTH并改善晚期癌症患者的治疗结果.
相关概念视频
Hypoglycemia and Glucagon
150
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
150
Diabetes: Management and Pharmacotherapy
233
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
233


